Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Clinical and Hematopoietic Profiles Associated with Sustained Hydroxyurea Response for Patients with Sickle Cell Disease

Luisanna M Sanchez Ventura, Ijele Adimora, Emani C. Elliot, Titilope Fasipe, Jonathan M. Flanagan

Blood (2023) 142 (Supplement 1): 17.

https://doi.org/10.1182/blood-2023-187335

Published: 2023

Journal Articles

Neighborhood Disadvantage Increases Risk of Adverse Clinical Events in Children with Sickle Cell Disease

Ijele Adimora, Luisanna M Sanchez Ventura, Jonathan M. Flanagan

Blood (2023) 142 (Supplement 1): 3905.

https://doi.org/10.1182/blood-2023-190445

Published: 2023

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Blood (2022) 140 (Supplement 1): 665–667.

https://doi.org/10.1182/blood-2022-160000

Published: 2022

Journal Articles

Exploration of Menarche, Dietary Iron, and Additional Risk Factors on the Development of Iron Deficiency in Adolescent Girls

Luisanna M. Sanchez Ventura, Sarah H. O'Brien, Joseph R Stanek, Jonathan M. Flanagan, Wendy Teuchter, Michael E. Scheurer, Jacquelyn M. Powers

Blood (2022) 140 (Supplement 1): 10871–10872.

https://doi.org/10.1182/blood-2022-169942

Published: 2022

Journal Articles

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Fernando Martín Moro, Leyre Bento De Miguel, Juan Marquet Palomanes, Antonio Gutierrez, Antonio Diaz-Lopez, Jose M. Sanchez, Jose Antonio Garcia Vela, Antonio Salar, Raul Cordoba, Silvana Novelli, Maria J. Rodriguez-Salazar, Sonia González de Villambrosia, Raquel Del Campo, Hugo Daniel Luzardo Henriquez, Daniel Garcia, Juan-Manuel Sancho, Pau Abrisqueta, Alejandro Martín García-Sancho, Mariana Bastos-Oreiro

Blood (2022) 140 (Supplement 1): 779–781.

https://doi.org/10.1182/blood-2022-170854

Published: 2022

Journal Articles

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 378–380.

https://doi.org/10.1182/blood-2022-169219

Published: 2022

Journal Articles

Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC)

Rosa Ayala, Rafael Alonso Fernández, Valentín Garcia Gutierrez, Alberto Alvarez-Larran, Santiago Osorio, Jose M. Sanchez, Gonzalo Carreño Gomez-Tarragona, María Teresa Gómez-Casares, Antonia Duran, Joaquín Martínez-López

Blood (2021) 138 (Supplement 1): 3655.

https://doi.org/10.1182/blood-2021-150240

Published: 2021

Journal Articles

Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain

Blood (2021) 138 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2021-147369

Published: 2021

Journal Articles

The neurotransmitter receptor Gabbr1 regulates proliferation and function of hematopoietic stem and progenitor cells

Lijian Shao, Adedamola Elujoba-Bridenstine, Katherine E. Zink, Laura M. Sanchez, Brian J. Cox, Karen E. Pollok, Anthony L. Sinn, Barbara J. Bailey, Emily C. Sims, Scott H. Cooper, Hal E. Broxmeyer, Kostandin V. Pajcini, Owen J. Tamplin

Blood (2021) 137 (6): 775–787.

https://doi.org/10.1182/blood.2019004415

Published: 2021

Includes: Supplemental data

Journal Articles

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Gloria Iacoboni, MD, Josu Iraola-Truchuelo, Nuria Martinez-Cibrian, MD, Rebeca Bailén, MD, Lucia Lopez Corral, PhD MD, Jose M. Sanchez, MD, Manuel Guerreiro, MD, ANA Carolina Carolina CABALLERO González, Alberto Mussetti, MD, Juan-Manuel Sancho, MD PhD, Rafael Hernani, MD, Carlos Solano, MD PhD, Anna Sureda Balari, MD PhD, Javier Briones, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD, Mi Kwon, MD PhD, Juan Luis Reguera, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136201

Published: 2020

Journal Articles

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Joaquin Martinez Lopez, Rafael Alonso Fernández, Sandy W. Wong, MD, Rafael Rios, MD PhD, Nina Shah, MD, Maria Teresa Cedena Romero, MD PhD, Yanira Ruiz-Heredia, Jose M. Sanchez, MD, Santiago Barrio Garcia, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140352

Published: 2020

Journal Articles

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

Blood (2018) 132 (Supplement 1): 47.

https://doi.org/10.1182/blood-2018-99-109976

Published: 2018

Journal Articles

Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era

Blood (2017) 130 (Supplement 1): 827.

https://doi.org/10.1182/blood.V130.Suppl_1.827.827

Published: 2017

Journal Articles

Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics

Ricardo Sanchez, Mireia Morgades, M.Prob.S, Rosa Ayala, Esther Onecha, Yanira Ruiz-Heredia, Jose M. Sanchez, Susana Vives, MD, Santiago Mercadal, MD, Ramón Guardia, Marta Cervera, MD, Olga García, Jordi Ribera, Josep-Maria Ribera, MD, Joaquín Martínez

Blood (2017) 130 (Supplement 1): 2710.

https://doi.org/10.1182/blood.V130.Suppl_1.2710.2710

Published: 2017

Journal Articles

Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy

Blood (2017) 130 (Supplement 1): 1559.

https://doi.org/10.1182/blood.V130.Suppl_1.1559.1559

Published: 2017

Journal Articles

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech)

Esther Onecha, Joan Ballesteros, Jose L Rojas, Jose M Sanchez, Eva Barragan, PhD, Inmaculada Rapado, PhD, Santiago Barrio, David Martinez, MD PhD, Pau Montesinos, MD, Pilar Herrera, MD PhD, Carmen Burgaleta, MD, Joaquin Martinez-López, MDPhD, Rosa M. Ayala, MD PhD

Blood (2015) 126 (23): 1376.

https://doi.org/10.1182/blood.V126.23.1376.1376

Published: 2015

Journal Articles

Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators

Blood (2012) 120 (21): 3593.

https://doi.org/10.1182/blood.V120.21.3593.3593

Published: 2012

Journal Articles

Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome,

Sandra Muntión, PhD, Carlos Santamaría, PhD, Beatriz Roson, Carlos Romo, Olga López-Villar, MD, PhD, Soraya Carrancio, PhD, Fermin M. Sanchez-Guijo, MD, PhD, María Diez-Campelo, MD, PhD, Maria-Eugenia Sarasquete, PhD, Javier de las Rivas, PhD, Marcos González, MD, Jesus F. San Miguel, MD, PhD, Maria-Consuelo del Cañizo, MD, PhD

Blood (2011) 118 (21): 3810.

https://doi.org/10.1182/blood.V118.21.3810.3810

Published: 2011

Journal Articles

Mesenchymal Stromal Cells From Myelodysplastic Syndrome Patients Show Lower DICER1 and DROSHA Expression, as Well as Decreased Mir-155 and Mir-181a MicroRNA Expression, When Compared with Healthy Controls

Carlos Santamaría, Olga López-VIllar, Sandra Muntión, Belén Blanco, Soraya Carrancio, Fermin M. Sanchez-Guijo, María Diez-Campelo, Stela Álvarez-Fernández, María E. Sarasquete, Marcos González, Jesús F. San Miguel, María C. Del Cañizo

Blood (2010) 116 (21): 397.

https://doi.org/10.1182/blood.V116.21.397.397

Published: 2010

Journal Articles

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Antonio Garcia-Gomez, Mercedes Garayoa, Enrique M. Ocio, Edvan Crusoe, Diego Fernández, Teresa Paíno, Laura San Segundo, Juan C. Montero, Stela Álvarez-Fernández, Juan F. Blanco, Fermin M. Sanchez-Guijo, Felix T. Garzon, Atanasio Pandiella, Jesús F. San-Miguel, MD, PhD

Blood (2009) 114 (22): 3834.

https://doi.org/10.1182/blood.V114.22.3834.3834

Published: 2009

NARROW

Clinical and Hematopoietic Profiles Associated with Sustained Hydroxyurea Response for Patients with Sickle Cell Disease

Neighborhood Disadvantage Increases Risk of Adverse Clinical Events in Children with Sickle Cell Disease

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Exploration of Menarche, Dietary Iron, and Additional Risk Factors on the Development of Iron Deficiency in Adolescent Girls

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC)

Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain

The neurotransmitter receptor Gabbr1 regulates proliferation and function of hematopoietic stem and progenitor cells

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era

Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics

Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech)

Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators

Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome,

Mesenchymal Stromal Cells From Myelodysplastic Syndrome Patients Show Lower DICER1 and DROSHA Expression, as Well as Decreased Mir-155 and Mir-181a MicroRNA Expression, When Compared with Healthy Controls

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only